Investing.com - Financial Markets Worldwide

Oncolytics Biotech stock maintains Buy rating at H.C. Wainwright

Published 10/07/2025, 12:42
Oncolytics Biotech stock maintains Buy rating at H.C. Wainwright
ONCY
3.81%

Investing.com - H.C. Wainwright reiterated a Buy rating and $5.00 price target on Oncolytics Biotech (NASDAQ:ONCY) on Wednesday, citing the company’s strategic focus under new leadership. The $113.69 million market cap company’s target price sits within the broader analyst range of $3.07 to $5.01, according to InvestingPro data.

The firm highlighted recent executive appointments, including Jared Kelly as CEO and Andrew Aromando as Chief Business Officer in June. Both executives previously played key roles in Johnson & Johnson’s $2 billion acquisition of Ambrx Biopharma in 2024.

H.C. Wainwright noted that Oncolytics is refining its regulatory and clinical strategy for registrational development of its lead oncolytic virus program, pelareorep, in two indications that have received FDA Fast Track designation: first-line metastatic pancreatic ductal adenocarcinoma and HR+/HER2- metastatic breast cancer.

The research firm pointed to Kelly’s July 8 strategy update, which emphasized that pelareorep has moved beyond proof-of-concept with survival data across multiple tumor types and is positioned for late-stage development.

H.C. Wainwright believes Oncolytics is approaching a key inflection point, with successful execution of its registrational strategy potentially unlocking meaningful value in 2025. Investors can access comprehensive analysis and 12 additional ProTips for ONCY through InvestingPro, including detailed insights ahead of the company’s next earnings report on August 6, 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.